Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations.
> To read the latest news about poziotinib, or to watch a video on its mechanism, click here.
Poziotinib is designed to be small and flexible.
Poziotinib is an investigational drug not approved by the FDA.
In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death.
Non Small Cell Lung Cancer
SPI-POZ-202 (Phase 2): EGFR and HER2 Exon 20 Insertion Mutations Locally Advanced or Metastatic NSCLC
Breast Cancer
SPI-POZ-201 (Phase 2): HER2+ Metastatic Breast Cancer
Spectrum Provides Poziotinib Update after Successful Pre-NDA Meeting with the FDA
Read MoreSpectrum Pharmaceuticals Provides Strategy Update for Poziotinib Development Program
Read MoreSpectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical Conference
Read MoreSpectrum Pharmaceuticals Provides Pipeline Update on Late Stage Programs
Read MoreSpectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell
Read MoreSpectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer
Read MoreSpectrum Announces Expansion of the Poziotinib Clinical Program
Read MoreSpectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations
Read Morehttp://investor.sppirx.com/index.php/news-releases/news-release-details/spectrum-announces-poziotinib-zenith20-trial-her2-cohort-cohort
Read MoreSpectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations
Read MoreSpectrum Pharmaceuticals Provides Poziotinib Update
Read MoreSpectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
Read MoreSpectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer
Read MoreExclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
Read MoreSpectrum Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific
Read MorePublication of Poziotinib Data in Nature Medicine
Read MoreData Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
Read MoreUpdate of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
Read MoreInitiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
Read MorePoziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
Read MoreInitiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Read MoreSpectrum Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Read MoreAbstracts on Poziotinib posted at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Read More